Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGIGANTE, Alexandre Duarte
dc.contributor.authorLAFER, Beny
dc.contributor.authorYATHAM, Lakshmi N.
dc.date.accessioned2013-07-30T15:19:00Z
dc.date.available2013-07-30T15:19:00Z
dc.date.issued2012
dc.description.abstractDepot antipsychotics have been used as a strategy to reduce non-adherence to medications in schizophrenia and bipolar disorder (BD). This article reviews the literature on the efficacy and safety of first- and second-generation depot antipsychotics (FGDA and SGDA, respectively) for the maintenance treatment of BD. Although FGDA have been studied in BD, they have not been approved for use in this disease. Among the SGDA, only depot risperidone has been studied and approved for the maintenance treatment of BD. We found eight studies on FGDA (three on flupenthixol, two on depot haloperidol, one on fluphenazine and flupenthixol, two on a mix of diverse antipsychotics) and ten studies on SODA (all on depot risperidone). Differences in efficacy and safety were found between the two classes of depot antipsychotics. Although FGDA may be effective in reducing manic relapses, they possibly increase the risk of worsening depression. Depot risperidone is effective as a maintenance treatment in BD with effect noted predominantly for preventing mania. However, no worsening in depression was observed. Depot risperidone also is better tolerated than FGDA, mainly in relation to extrapyramidal symptoms. Studies with the new depot antipsychotics, olanzapine pamoate and paliperidone palmitate, are needed in BD patients. Further, there is currently little information on the metabolic changes (apart from bodyweight gain) that may occur with the use of depot risperidone in patients with bipolar disorder, and this issue needs further investigation.
dc.description.indexMEDLINE
dc.description.sponsorshipAstrazeneca
dc.description.sponsorshipJanssen
dc.description.sponsorshipLilly
dc.description.sponsorshipBristol Myers Squibb
dc.description.sponsorshipPfizer
dc.description.sponsorshipGSK
dc.description.sponsorshipMerck
dc.description.sponsorshipLundbeck
dc.description.sponsorshipServier
dc.description.sponsorshipForest
dc.identifier.citationCNS DRUGS, v.26, n.5, p.403-420, 2012
dc.identifier.doi10.2165/11631310-000000000-00000
dc.identifier.issn1172-7047
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1110
dc.language.isoeng
dc.publisherADIS INT LTD
dc.relation.ispartofCNS Drugs
dc.rightsrestrictedAccess
dc.rights.holderCopyright ADIS INT LTD
dc.subject.otheri disorder
dc.subject.otherfunctional impairment
dc.subject.otherdepot antipsychotics
dc.subject.otherlithium treatment
dc.subject.otherrisperidone
dc.subject.otheradherence
dc.subject.otherdiscontinuation
dc.subject.othermedication
dc.subject.othertherapy
dc.subject.otherrelapse
dc.subject.wosClinical Neurology
dc.subject.wosPharmacology & Pharmacy
dc.subject.wosPsychiatry
dc.titleLong-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisoca
hcfmusp.author.externalYATHAM, Lakshmi N.:Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada
hcfmusp.citation.scopus46
hcfmusp.contributor.author-fmusphcALEXANDRE DUARTE GIGANTE
hcfmusp.contributor.author-fmusphcBENY LAFER
hcfmusp.description.beginpage403
hcfmusp.description.endpage420
hcfmusp.description.issue5
hcfmusp.description.volume26
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22494448
hcfmusp.origem.scopus2-s2.0-84859961570
hcfmusp.origem.wosWOS:000304072800004
hcfmusp.publisher.cityAUCKLAND
hcfmusp.publisher.countryNEW ZEALAND
hcfmusp.relation.referenceAHLFORS UG, 1981, ACTA PSYCHIAT SCAND, V64, P226, DOI 10.1111/j.1600-0447.1981.tb00778.x
hcfmusp.relation.referenceAngst Jules, 2005, Arch Suicide Res, V9, P279, DOI 10.1080/13811110590929488
hcfmusp.relation.referenceBates JA, 2010, PRIM CARE COMPANION, V12
hcfmusp.relation.referenceBenabarre A, 2009, ACTAS ESP PSIQUIATRI, V37, P143
hcfmusp.relation.referenceBraunig P, 2008, INT J PSYCHIAT CLIN, V12, P74, DOI 10.1080/13651500701538161
hcfmusp.relation.referenceBrnabic AJM, 2011, INT J CLIN PRACT, V65, P945, DOI 10.1111/j.1742-1241.2011.02743.x
hcfmusp.relation.referenceCavanagh J, 2004, ACTA PSYCHIAT SCAND, V109, P91, DOI 10.1046/j.1600-0447.2003.00274.x
hcfmusp.relation.referenceESPARON J, 1986, BRIT J PSYCHIAT, V148, P723, DOI 10.1192/bjp.148.6.723
hcfmusp.relation.referenceFu-I L, 2009, J CLIN PSYCHIAT, V70, P604
hcfmusp.relation.referenceGonzalez-Pinto A, 2006, BIPOLAR DISORD, V8, P618, DOI 10.1111/j.1399-5618.2006.00368.x
hcfmusp.relation.referenceGonzalez-Pinto A, 2010, Pharmacopsychiatry, V43, P263, DOI 10.1055/s-0030-1263169
hcfmusp.relation.referenceHaddad Peter M, 2009, Br J Psychiatry Suppl, V52, pS20, DOI 10.1192/bjp.195.52.s20
hcfmusp.relation.referenceHan C, 2007, PROG NEURO-PSYCHOPH, V31, P1219, DOI 10.1016/j.pnpbp.2007.04.017
hcfmusp.relation.referenceHong JH, 2011, PSYCHIAT RES, V190, P110, DOI 10.1016/j.psychres.2011.04.016
hcfmusp.relation.referenceKane John M, 2006, CNS Spectr, V11, P1
hcfmusp.relation.referenceKauer-Sant'Anna M, 2009, COMPR PSYCHIAT, V50, P1, DOI 10.1016/j.comppsych.2008.05.013
hcfmusp.relation.referenceLeucht C, 2011, SCHIZOPHR RES, V127, P83, DOI 10.1016/j.schres.2010.11.020
hcfmusp.relation.referenceLingam R, 2002, ACTA PSYCHIAT SCAND, V105, P164, DOI 10.1034/j.1600-0447.2002.1r084.x
hcfmusp.relation.referenceLITTLEJOHN R, 1994, BRIT J PSYCHIAT, V165, P827, DOI 10.1192/bjp.165.6.827
hcfmusp.relation.referenceLopez-Jaramillo C, 2010, BIPOLAR DISORD, V12, P557, DOI 10.1111/j.1399-5618.2010.00835.x
hcfmusp.relation.referenceLOWE MR, 1985, BRIT J PSYCHIAT, V146, P558
hcfmusp.relation.referenceLOWE MR, 1986, INT CLIN PSYCHOPHARM, V1, P53
hcfmusp.relation.referenceMacfadden W, 2009, BIPOLAR DISORD, V11, P827, DOI 10.1111/j.1399-5618.2009.00761.x
hcfmusp.relation.referenceMacQueen GM, 2001, ACTA PSYCHIAT SCAND, V103, P163, DOI 10.1034/j.1600-0447.2001.00059.x
hcfmusp.relation.referenceMalempati RN, 2008, INT CLIN PSYCHOPHARM, V23, P88, DOI 10.1097/YIC.0b013e3282f2b4c5
hcfmusp.relation.referenceMcEvoy JP, 2006, J CLIN PSYCHIAT, V67, P15
hcfmusp.relation.referenceMerikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543
hcfmusp.relation.referenceMiklowitz DJ, 2011, CURR PSYCHIAT REP, V13, P504, DOI 10.1007/s11920-011-0227-x
hcfmusp.relation.referenceMULLEROERLINGHAUSEN B, 1992, J AFFECT DISORDERS, V25, P261, DOI 10.1016/0165-0327(92)90084-J
hcfmusp.relation.referenceNAYLOR GJ, 1980, BRIT J PSYCHIAT, V136, P105
hcfmusp.relation.referencePerlis RH, 2010, J CLIN PSYCHIAT, V71, P296, DOI 10.4088/JCP.09m05514yel
hcfmusp.relation.referenceQuiroz JA, 2010, BIOL PSYCHIAT, V68, P156, DOI 10.1016/j.biopsych.2010.01.015
hcfmusp.relation.referenceRosa AR, 2010, VALUE HEALTH, V13, P984, DOI 10.1111/j.1524-4733.2010.00768.x
hcfmusp.relation.referenceRosa AR, 2009, BIPOLAR DISORD, V11, P401, DOI 10.1111/j.1399-5618.2009.00698.x
hcfmusp.relation.referenceSavas HA, 2006, J CLIN PSYCHOPHARM, V26, P530, DOI 10.1097/01.jcp.0000231609.91144.00
hcfmusp.relation.referenceScott J, 2002, AM J PSYCHIAT, V159, P1927, DOI 10.1176/appi.ajp.159.11.1927
hcfmusp.relation.referenceSUPPES T, 1991, ARCH GEN PSYCHIAT, V48, P1082
hcfmusp.relation.referenceTaylor David, 2009, Br J Psychiatry Suppl, V52, pS13, DOI 10.1192/bjp.195.52.s13
hcfmusp.relation.referenceTohen M, 2000, AM J PSYCHIAT, V157, P220, DOI 10.1176/appi.ajp.157.2.220
hcfmusp.relation.referenceTorres I.J., 2007, ACTA PSYCHIAT SCAND, V434, P17
hcfmusp.relation.referenceVieta E, 2008, WORLD J BIOL PSYCHIA, V9, P219, DOI 10.1080/15622970701530917
hcfmusp.relation.referenceWHITE E, 1993, INT CLIN PSYCHOPHARM, V8, P119, DOI 10.1097/00004850-199300820-00007
hcfmusp.relation.referenceYatham L N, 2007, Acta Psychiatr Scand Suppl, P50
hcfmusp.remissive.sponsorshipAstraZeneca
hcfmusp.remissive.sponsorshipBristol-Myers Squibb
hcfmusp.remissive.sponsorshipJanssen
hcfmusp.remissive.sponsorshipLilly
hcfmusp.remissive.sponsorshipLundbeck
hcfmusp.remissive.sponsorshipMerck
hcfmusp.remissive.sponsorshipPfizer
hcfmusp.remissive.sponsorshipServier
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication92c483bc-68a3-4ff4-af54-589c3fd2ea75
relation.isAuthorOfPublication717693ba-66ff-4dac-9ac5-86d07eafb715
relation.isAuthorOfPublication.latestForDiscovery92c483bc-68a3-4ff4-af54-589c3fd2ea75
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_FORLENZA_Does_Lithium_Prevent_Alzheimer_s_Disease_2012.PDF
Tamanho:
256 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21